Ace Therapeutics Unveils Imaging Services for Precise Characterization of IBD Animal Models
New York, USA – May 28, 2025 – Ace Therapeutics, a leader in preclinical research solutions, launched its translational imaging solutions specifically designed to accurately characterize Inflammatory Bowel Disease (IBD) animal models. This breakthrough offering empowers researchers with high-resolution, quantitative data to enhance drug development and mechanistic studies.
Imaging techniques play a crucial role in studying inflammatory bowel disease in animal models, enabling non-invasive or minimally invasive visualization of disease progression, inflammation, and treatment efficacy. Key imaging modalities used in preclinical IBD research include endoscopic imaging with advantages of real-time assessment and scoring of disease activity, optical imaging (high sensitivity, dynamic monitoring of disease progression), magnetic resonance imaging (MRI), ultrasound imaging, as well as positron emission tomography/computed tomography (PET/CT). The choice of imaging technologies depends on the research question, required resolution, and need for functional vs. structural data, and combining techniques (e.g., PET-MRI) can provide the most comprehensive insights.
Ace Therapeutics possesses well-established imaging technology platforms designed to meet clients’ imaging requirements in animal models of inflammatory bowel disease. The company’s advanced imaging techniques facilitate not only direct visualization of intestinal inflammation but also enable molecular imaging and targeting of specific alterations in the inflamed murine mucosa.
Why Choose Ace Therapeutics’ Imaging Services?
High-Resolution Imaging Platforms: Utilize ultrasound, optical imaging, MRI, and PET/CT for detailed visualization of gastrointestinal pathology.
Quantitative Data Analysis: Beyond traditional qualitative assessments, Ace Therapeutics’ expert team can provide quantitative metrics (e.g., mucosal CD4+ T cells, stem cell tracking, changes in the gut microbiome) to standardize preclinical evaluations.
Customizable Workflows: Tailored protocols for murine models of Crohn’s disease and ulcerative colitis ensure alignment with customers’ specific research goals, from longitudinal studies to acute intervention analysis.
“Our preclinical IBD imaging services eliminate the guesswork in IBD model characterization. By delivering objective, high-fidelity data, we help researchers make confident decisions in drug discovery and translational studies,” said the business development manager at Ace Therapeutics. “Whether you’re evaluating novel therapeutics or investigating disease mechanisms, Ace Therapeutics’ imaging services provide the precision and reliability you need.” For pricing, sample reports, or a personalized demo, contact the Ace Therapeutics team at [email protected] or visit www.acetherapeutics.com/ibd.
About Ace Therapeutics
Ace Therapeutics is a globally recognized provider of inflammatory bowel disease (IBD) research services. The company offers solutions to advance basic IBD research, experimental modeling, and preclinical drug studies. Its services and expertise support clients in developing effective IBD therapies through consistent and high-quality data. With extensive experience in advancing novel therapeutic agents from early-stage in vitro testing to candidate nomination, Ace Therapeutics’ technical team provides guidance on appropriate models and customized protocols aligned with research objectives.
Follow Us on: Facebook | Twitter | LinkedIn
Media Contact
Company Name: Ace Therapeutics
Contact Person: Daisy Mostert
Email: Send Email
Phone: 1-516-441-0167
Country: United States
Website: https://www.acetherapeutics.com/ibd
